Focus: Valencia Technologies is a neuromodulation-focused biotech company developing the eCoin system for bladder dysfunction and resistant hypertension. The company operates at an early stage with a focused pipeline and limited public disclosure of scale.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Valencia represents a high-risk, early-stage bet on neuromodulation with limited hiring velocity and opaque financials—suitable only for founders/early employees seeking equity upside, not career stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Valencia Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Valencia Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles